Anthrax vaccine adsorbed (AVA)
GPTKB entity
Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Anthrax
gptkb:injection_anthrax |
| gptkbp:approves |
gptkb:1970
gptkb:U._S._Food_and_Drug_Administration |
| gptkbp:clinical_trial |
Phase I, II, and III trials
|
| gptkbp:developed_by |
gptkb:U._S._Army_Medical_Research_Institute_of_Infectious_Diseases
|
| gptkbp:dosage_form |
suspension
|
| https://www.w3.org/2000/01/rdf-schema#label |
Anthrax vaccine adsorbed (AVA)
|
| gptkbp:indication |
prevention of anthrax infection
|
| gptkbp:is_vulnerable_to |
inactivated vaccine
approximately 93% |
| gptkbp:manager |
intramuscular injection
|
| gptkbp:manufacturer |
gptkb:Emergent_Bio_Solutions
|
| gptkbp:requires |
every 6 to 12 months
|
| gptkbp:side_effect |
local reactions
systemic reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:suitable_for |
high-risk individuals
|
| gptkbp:targets |
gptkb:mythological_figure
|